NASDAQ$OABI
OmniAb Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
OmniAb's financial results for Q3 2022 were reported, highlighting revenue growth driven by higher royalty revenue and increased expenses due to investments in R&D and preparations for becoming an independent company.
OmniAb reported revenue of $6.9 million for the third quarter of 2022, compared to $6.3 million for the same period in 2021. The net loss for the quarter was $12.6 million, compared to a net loss of $7.9 million in 2021.
- Revenue increased to $6.9 million, driven by higher royalty revenue from zimberelimab and sugemalimab in China.
- Research and development expenses rose to $13.2 million due to investments in facilities, headcount, and technology innovation.
- General and administrative expenses increased to $5.6 million due to headcount-related expenditures for becoming an independent company.
- Net loss was $12.6 million, compared to a net loss of $7.9 million for the same period in 2021.
Headline financials
Revenue & EPS history
OmniAb · Revenue · Quarterly
$6.91M
Revenue by segment
OmniAb · $5.48M total across 3 segments · Q3 2023
- Service Revenue$3.02M—55.1%
- License and Milestone$2.01M—36.7%
- Royalty Revenue$451K—8.2%
Forward guidance
OmniAb expects its cash and cash generated from operations to fund operations for the foreseeable future.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2022
-2.1%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+9.9%
Q4 2025
Best reaction
-20.4%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +29.4% | +72.7% | |
| Q4 2025 | +9.9% | +9.9% | -14.9% | |
| Q3 2025 | -4.1% | +0.7% | +31.8% | |
| Q1 2025 | -7.2% | -3.2% | -4.5% | |
| Q4 2024 | -20.4% | -20.4% | -43.9% | |
| Q3 2024 | -11.5% | -15.7% | -13.0% | |
| Q2 2024 | +4.4% | +4.9% | -2.2% | |
| Q1 2024 | +3.1% | -0.9% | +2.2% | |
| Q4 2023 | -2.5% | +0.8% | -11.4% | |
| Q3 2023 | -6.8% | +3.5% | +7.3% | |
| Q2 2023 | -5.7% | -3.8% | -10.4% | |
| Q1 2023 | +6.1% | +16.1% | +37.3% | |
| Q4 2022 | +9.5% | +10.1% | +3.6% | |
| Q3 2022 | -15.5% | -4.1% | +19.3% | |
| Q2 2022 | +0.2% | +0.1% | +0.3% | |
| Q1 2022 | -0.0% | +0.0% | +0.1% | |
| Q4 2021 | -0.0% | -0.1% | -0.1% | |
| Q3 2021 | +0.0% | +0.0% | -0.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro